{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:20:13Z","timestamp":1790306413543,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T00:00:00Z","timestamp":1506297600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11899-017-0401-2","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T03:04:40Z","timestamp":1506308680000},"page":"397-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature"],"prefix":"10.1007","volume":"12","author":[{"given":"Amy","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,25]]},"reference":[{"issue":"20","key":"401_CR1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"5","key":"401_CR2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573\u201382.","journal-title":"J Clin Oncol"},{"issue":"25","key":"401_CR3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"\u2022\u2022 Nangalia J, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405. This paper provides one of the first descriptions of mutations in CALR in ET and PMF.","journal-title":"N Engl J Med"},{"issue":"25","key":"401_CR4","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"\u2022\u2022 Klampfl T, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390. This paper provides one of the first descriptions of mutations in CALR in ET and PMF and suggests a more favorable prognosis for patients with CALR mutations.","journal-title":"N Engl J Med"},{"issue":"10","key":"401_CR5","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472\u20136.","journal-title":"Blood"},{"issue":"2","key":"401_CR6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","volume":"149","author":"EM Boyd","year":"2010","unstructured":"Boyd EM, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol. 2010;149(2):250\u20137.","journal-title":"Br J Haematol"},{"issue":"12","key":"401_CR7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/leu.2011.161","volume":"25","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011;25(12):1834\u20139.","journal-title":"Leukemia"},{"issue":"3","key":"401_CR8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","volume":"128","author":"MA Elliott","year":"2005","unstructured":"Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275\u201390.","journal-title":"Br J Haematol"},{"issue":"5","key":"401_CR9","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.leukres.2010.07.031","volume":"35","author":"SJ Noor","year":"2011","unstructured":"Noor SJ, et al. Myeloid blastic transformation of myeloproliferative neoplasms\u2014a review of 112 cases. Leuk Res. 2011;35(5):608\u201313.","journal-title":"Leuk Res"},{"issue":"17","key":"401_CR10","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410\u20135.","journal-title":"J Clin Oncol"},{"issue":"16","key":"401_CR11","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"\u2022 Tefferi A, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313. quiz 2615. This paper is one of the largest cohort studies examining the prognostic impact of driver mutations (JAK2\/CALR\/MPL) on survival in ET, PV, and PMF.","journal-title":"Blood"},{"issue":"24","key":"401_CR12","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995\u20133001.","journal-title":"J Clin Oncol"},{"issue":"13","key":"401_CR13","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood"},{"issue":"9","key":"401_CR14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703\u20138.","journal-title":"Blood"},{"issue":"4","key":"401_CR15","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392\u20137.","journal-title":"J Clin Oncol"},{"issue":"26","key":"401_CR16","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128\u201333.","journal-title":"Blood"},{"key":"401_CR17","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.","journal-title":"Blood Cancer J"},{"key":"401_CR18","doi-asserted-by":"crossref","unstructured":"Ospedali R, Barbui T, Finazzi G, de Gaetano G, Marchioli R, Tognoni G, et al. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123(9):656\u201364.","DOI":"10.7326\/0003-4819-123-9-199511010-00003"},{"issue":"10","key":"401_CR19","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224\u201332.","journal-title":"J Clin Oncol"},{"issue":"3","key":"401_CR20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","volume":"138","author":"N Gangat","year":"2007","unstructured":"Gangat N, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354\u20138.","journal-title":"Br J Haematol"},{"issue":"1","key":"401_CR21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","volume":"92","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92(1):94\u2013108.","journal-title":"Am J Hematol"},{"issue":"9","key":"401_CR22","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"\u2022\u2022 Tefferi A, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874\u201381. This paper is one of the largest cohort studies on the outcome of patients with PV and the clinical prognostic factors that impact survival.","journal-title":"Leukemia"},{"issue":"1","key":"401_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22\u201333.","journal-title":"N Engl J Med"},{"key":"401_CR24","doi-asserted-by":"crossref","first-page":"794240","DOI":"10.1155\/2011\/794240","volume":"2011","author":"R Marchioli","year":"2011","unstructured":"Marchioli R, et al. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis. 2011;2011:794240.","journal-title":"Thrombosis"},{"issue":"1","key":"401_CR25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2016.152769","volume":"102","author":"A Alvarez-Larran","year":"2017","unstructured":"Alvarez-Larran A, et al. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica. 2017;102(1):103\u20139.","journal-title":"Haematologica"},{"issue":"17","key":"401_CR26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMc1502524","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(17):1670\u20131.","journal-title":"N Engl J Med"},{"issue":"7","key":"401_CR27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","volume":"101","author":"S Verstovsek","year":"2016","unstructured":"Verstovsek S, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821\u20139.","journal-title":"Haematologica"},{"issue":"2","key":"401_CR28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","volume":"86","author":"K Abdulkarim","year":"2011","unstructured":"Abdulkarim K, et al. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011;86(2):148\u201355.","journal-title":"Eur J Haematol"},{"issue":"2","key":"401_CR29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000083452","volume":"113","author":"A Kreft","year":"2005","unstructured":"Kreft A, et al. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113(2):137\u201343.","journal-title":"Acta Haematol"},{"issue":"11","key":"401_CR30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s002770050546","volume":"78","author":"J Thiele","year":"1999","unstructured":"Thiele J, Kvasnicka HM, Fischer R. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders\u2014aids to diagnosis and classification. Ann Hematol. 1999;78(11):495\u2013506.","journal-title":"Ann Hematol"},{"issue":"10","key":"401_CR31","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","volume":"119","author":"T Barbui","year":"2012","unstructured":"Barbui T, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119(10):2239\u201341.","journal-title":"Blood"},{"issue":"3","key":"401_CR32","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1038\/bcj.2017.17","volume":"7","author":"D Barraco","year":"2017","unstructured":"Barraco D, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017;7(3):e538.","journal-title":"Blood Cancer J"},{"issue":"5","key":"401_CR33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459\u201368.","journal-title":"N Engl J Med"},{"issue":"8","key":"401_CR34","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","volume":"86","author":"LM Scott","year":"2011","unstructured":"Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86(8):668\u201376.","journal-title":"Am J Hematol"},{"issue":"10","key":"401_CR35","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","volume":"117","author":"F Passamonti","year":"2011","unstructured":"Passamonti F, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117(10):2813\u20136.","journal-title":"Blood"},{"issue":"6","key":"401_CR36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","volume":"129","author":"W Vainchenker","year":"2017","unstructured":"Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667\u201379.","journal-title":"Blood"},{"issue":"1","key":"401_CR37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"\u2022\u2022 Tefferi A, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances. 2016;1(1):21\u201330. This paper provides one of the first descriptions of the frequency of non-driver mutations in PV and ET and their prognostic impact.","journal-title":"Blood Advances"},{"issue":"9","key":"401_CR38","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","volume":"28","author":"P Guglielmelli","year":"2014","unstructured":"\u2022 Guglielmelli P, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014;28(9):1804\u201310. This paper is one of the first to demonstrate that the number of adverse non-driver mutations impacts survival in PMF.","journal-title":"Leukemia"},{"issue":"10","key":"401_CR39","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755\u201361.","journal-title":"Am J Med"},{"issue":"23","key":"401_CR40","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179\u201384.","journal-title":"J Clin Oncol"},{"issue":"2","key":"401_CR41","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","volume":"21","author":"N Gangat","year":"2007","unstructured":"Gangat N, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270\u20136.","journal-title":"Leukemia"},{"issue":"6","key":"401_CR42","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197\u2013201.","journal-title":"Blood"},{"issue":"6","key":"401_CR43","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680\u201392.","journal-title":"Blood"},{"issue":"4","key":"401_CR44","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","volume":"91","author":"M Haider","year":"2016","unstructured":"Haider M, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016;91(4):390\u20134.","journal-title":"Am J Hematol"},{"issue":"11","key":"401_CR45","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","volume":"109","author":"J Kittur","year":"2007","unstructured":"Kittur J, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109(11):2279\u201384.","journal-title":"Cancer"},{"issue":"9501","key":"401_CR46","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945\u201353.","journal-title":"Lancet"},{"issue":"11","key":"401_CR47","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1182\/blood.V99.11.4228","volume":"99","author":"M Picardi","year":"2002","unstructured":"Picardi M, et al. Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study. Blood. 2002;99(11):4228\u201330.","journal-title":"Blood"},{"issue":"3","key":"401_CR48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.24269","volume":"91","author":"A Andriani","year":"2016","unstructured":"Andriani A, et al. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1297 patients. Am J Hematol. 2016;91(3):318\u201321.","journal-title":"Am J Hematol"},{"issue":"3","key":"401_CR49","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis. Blood. 2012;120(3):569\u201371.","journal-title":"Blood"},{"issue":"5","key":"401_CR50","doi-asserted-by":"crossref","first-page":"E296","DOI":"10.1002\/ajh.24334","volume":"91","author":"M Haider","year":"2016","unstructured":"Haider M, et al. Splenomegaly and thrombosis risk in essential thrombocythemia: the Mayo Clinic experience. Am J Hematol. 2016;91(5):E296\u20137.","journal-title":"Am J Hematol"},{"issue":"12","key":"401_CR51","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","volume":"28","author":"A Tefferi","year":"2014","unstructured":"\u2022 Tefferi A, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014;28(12):2300\u20133. This paper was one of the first studies to evaluate the impact of CALR mutations on survival in a large ET cohort.","journal-title":"Leukemia"},{"issue":"9","key":"401_CR52","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"\u2022\u2022 Vannucchi AM, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861\u20139. This paper is one of the first to evaluate the impact of non-driver mutations in PMF and identified ASXL1, SRSF2, EZH2, and IDH1\/2 as adverse prognostic factors associated with decreased survival and increased leukemic transformation.","journal-title":"Leukemia"},{"issue":"3","key":"401_CR53","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/leu.2011.232","volume":"26","author":"V Visconte","year":"2012","unstructured":"Visconte V, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia. 2012;26(3):542\u20135.","journal-title":"Leukemia"},{"issue":"7","key":"401_CR54","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2011.053918","volume":"97","author":"J Broseus","year":"2012","unstructured":"Broseus J, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97(7):1036\u201341.","journal-title":"Haematologica"},{"issue":"5","key":"401_CR55","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905\u201314.","journal-title":"Leukemia"},{"issue":"3","key":"401_CR56","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","volume":"105","author":"RA Mesa","year":"2005","unstructured":"Mesa RA, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973\u20137.","journal-title":"Blood"},{"issue":"2","key":"401_CR57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.beha.2014.07.008","volume":"27","author":"A Zhou","year":"2014","unstructured":"Zhou A, Oh ST. Prognostication in MF: from CBC to cytogenetics to molecular markers. Best Pract Res Clin Haematol. 2014;27(2):155\u201364.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"401_CR58","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"Caramazza D, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82\u20138.","journal-title":"Leukemia"},{"issue":"2","key":"401_CR59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1600-0609.2009.01373.x","volume":"84","author":"MM Patnaik","year":"2010","unstructured":"Patnaik MM, et al. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. Eur J Haematol. 2010;84(2):105\u20138.","journal-title":"Eur J Haematol"},{"issue":"9","key":"401_CR60","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ajh.24442","volume":"91","author":"P Guglielmelli","year":"2016","unstructured":"Guglielmelli P, et al. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016;91(9):918\u201322.","journal-title":"Am J Hematol"},{"issue":"19","key":"401_CR61","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","volume":"118","author":"P Guglielmelli","year":"2011","unstructured":"Guglielmelli P, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011;118(19):5227\u201334.","journal-title":"Blood"},{"issue":"12","key":"401_CR62","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1038\/bcj.2016.116","volume":"6","author":"B Li","year":"2016","unstructured":"Li B, et al. Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis. Blood Cancer J. 2016;6(12):e505.","journal-title":"Blood Cancer J"},{"issue":"12","key":"401_CR63","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood. 2007;110(12):4030\u20136.","journal-title":"Blood"},{"issue":"5","key":"401_CR64","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","volume":"107","author":"PJ Campbell","year":"2006","unstructured":"Campbell PJ, et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood. 2006;107(5):2098\u2013100.","journal-title":"Blood"},{"issue":"4","key":"401_CR65","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","volume":"22","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008;22(4):756\u201361.","journal-title":"Leukemia"},{"issue":"8","key":"401_CR66","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","volume":"114","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114(8):1477\u201383.","journal-title":"Blood"},{"issue":"1","key":"401_CR67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3324\/haematol.13721","volume":"94","author":"P Guglielmelli","year":"2009","unstructured":"Guglielmelli P, et al. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Haematologica. 2009;94(1):144\u20136.","journal-title":"Haematologica"},{"issue":"7","key":"401_CR68","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"\u2022 Tefferi A, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472\u20137. This study was one of the first to evaluate the prognostic impact of JAK2\/CALR\/MPL mutations on a large PMF cohort.","journal-title":"Leukemia"},{"issue":"9","key":"401_CR69","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00277-016-2712-0","volume":"95","author":"YQ Pei","year":"2016","unstructured":"Pei YQ, et al. Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Ann Hematol. 2016;95(9):1391\u20138.","journal-title":"Ann Hematol"},{"issue":"15","key":"401_CR70","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","volume":"124","author":"A Tefferi","year":"2014","unstructured":"\u2022 Tefferi A, et al. The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood. 2014;124(15):2465\u20136. This paper is one of the first to report on a difference in prognostic impact between type-1 and type-2 CALR mutations.","journal-title":"Blood"},{"issue":"7","key":"401_CR71","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"\u2022 Rumi E, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062\u20139. This study was one of the first to evaluate the prognostic impact of JAK2\/CALR\/MPL mutations on survival in a large PMF cohort.","journal-title":"Blood"},{"issue":"7","key":"401_CR72","doi-asserted-by":"crossref","first-page":"E320","DOI":"10.1002\/ajh.24378","volume":"91","author":"B Li","year":"2016","unstructured":"Li B, et al. The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis. Am J Hematol. 2016;91(7):E320\u20131.","journal-title":"Am J Hematol"},{"key":"401_CR73","doi-asserted-by":"publisher","unstructured":"Kourie HR, Ameye L, Paesmans M, Bron D. Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis. Br J Haematol. 2016. \nhttps:\/\/doi.org\/10.1111\/bjh.14259\n\n.","DOI":"10.1111\/bjh.14259"},{"issue":"2","key":"401_CR74","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431\u20138.","journal-title":"Leukemia"},{"issue":"10","key":"401_CR75","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","volume":"127","author":"C Marty","year":"2016","unstructured":"\u2022\u2022 Marty C, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127(10):1317\u201324. This paper was one of the first to demonstrate the effect of CALR mutations in mice and the difference in phenotype generated by type-1 and type-2 mutations.","journal-title":"Blood"},{"issue":"2","key":"401_CR76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2013.286","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2014;28(2):431\u20133.","journal-title":"Leukemia"},{"key":"401_CR77","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.1038\/bcj.2016.24","volume":"6","author":"D Barraco","year":"2016","unstructured":"Barraco D, et al. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J. 2016;6:e416.","journal-title":"Blood Cancer J"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-017-0401-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0401-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-017-0401-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T07:53:36Z","timestamp":1509695616000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-017-0401-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,25]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s11899-017-0401-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,25]]}}}